Longbio Pharma (Suzhou) Co (HKSE:01779) Construction In Progress: HK$1.38 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$113.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co Construction In Progress?

Longbio Pharma (Suzhou) Co HKSE:01779 +5.51% 10 Construction In Progress is HK$1.38 Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Longbio Pharma (Suzhou) Co's quarterly construction in progress stayed the same from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$0.00 Mil) but then increased from Dec. 2024 (HK$0.00 Mil) to Dec. 2025 (HK$1.38 Mil).

Longbio Pharma (Suzhou) Co's annual construction in progress stayed the same from . 20 (HK$0.00 Mil) to Dec. 2024 (HK$0.00 Mil) but then increased from Dec. 2024 (HK$0.00 Mil) to Dec. 2025 (HK$1.38 Mil).

Longbio Pharma (Suzhou) Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Construction In Progress Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Construction In Progress
0.00 1.38

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Construction In Progress 0.00 1.38
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$1.38 Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Construction In Progress of HK$1.38 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Longbio Pharma (Suzhou) Co and its competitors.
Is Longbio Pharma (Suzhou) Co's Construction In Progress too high?
Longbio Pharma (Suzhou) Co's current Construction In Progress is HK$1.38 Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Construction In Progress compare to VRTX and REGN?
Longbio Pharma (Suzhou) Co's Construction In Progress of HK$1.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Construction In Progress is HK$1.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Construction In Progress of HK$1.38 Mil. The current Construction In Progress is HK$1.38 Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Construction In Progress is HK$1.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$113.00
Price